CG Oncology, Inc. CGON
No buyback or stock pay figures in its 10-K data yet
XBRL, 10-KCash runway
Cash on the balance sheet of Sep 30, 2026 against the operating cash it used over the last four quarters · XBRL
Shown only when operating cash flow of the last twelve months is negative. A fact about the past twelve months, not a forecast: the company can raise money, cut costs or change pace. Debt due is on the Debt tab; share sales are in the dilution card below.
New shares against shares bought back
Dilution: new shares, stock pay and buybacks · S-3 and 424B, 3 years; 10-K
Shares offered
Since Nov 17, 2023: 2 at-the-market programs, 1 sale of new shares, 5 shelf registrations; also 2 resales by holders.
- Aug 6, 2026 At-the-market program: up to $550M of common stock 424B5
- Jan 13, 2026 At-the-market program: up to $250M of common stock 424B5
- Mar 28, 2025 Shelf registration: shares and other securities, amount not fixed S-3ASR
- Dec 11, 2024 Shelf registration: shares and other securities, amount not fixed S-1/A
- Jan 25, 2024 Sale of 20.0M new shares 424B4
- Jan 23, 2024 Shelf registration: shares and other securities, amount not fixed S-1/A
Every offering filing“aggregate offering price of up to $550.0 million pursuant to the terms of that certain Open Market Sale AgreementSM (the sales agreement) dated March 28, 2025, with Jefferies LLC (Jefferies).”
424B5, Aug 6, 2026
Paid in stock and bought back
No stock pay or buyback lines in the 10-K XBRL.
Where the cash came from and where it went
FY2025, from the cash flow statement in the 10-K, added up
The same cash, step by step
Came from
| Shares sold | $147.4M |
| Cash on hand used | $224.6M |
Went to
| Operating cash flow (outflow) | $132.3M |
| Capital spending | $134K |
| Acquisitions | $22.0M |
| Other, net investments bought and sold, other financing and investing lines, and exchange rates |
$217.6M |
Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.
Where the operating cash went, year by year
FY2023 to FY2025 · cash flow statements, 10-K XBRL
| Fiscal year | Operating cash | Capital spending | Acquisitions |
|---|---|---|---|
| Dec 31, 2025 | -$132.3M | $134K | $22.0M |
| Dec 31, 2024 | -$78.7M | $234K | - |
| Dec 31, 2023 | -$45.7M | - | - |
| Added up | -$256.7M | $368K | $22.0M |
Each bar is one fiscal year; its colours add up to what the cash flow statement says the company spent on each line, and the line across it is that year's operating cash flow. Spending above the line was paid from new debt, shares sold or cash on hand. A bar part links to the 10-K it comes from. A line the company did not report is left out, not estimated, so the shares are of operating cash only and can add up to more or less than 100%. Debt repaid is the gross amount, so refinanced debt is counted each time it is repaid. A reading aid, not a grade: Tickdelta does not say whether a split was good. Banks and insurers are left out.
Buybacks, dividends and share count
Year by year · XBRL, each 10-K
No buyback or share count data in the 10-K XBRL.
What the 10-Ks show for each CEO's years
Each CEO's years · the CEO of each fiscal year as named in the proxy's pay versus performance table
Arthur Kuan
- Operating cash flow
- -$211.1M
- Capital spending
- $368K
- Acquisitions
- $22.0M
- Stock-based pay
- $38.1M
- Diluted shares since FY2023
- +19.0%
- Revenue since FY2023
- +1880%
- CEO pay (reported)
- $23.1M
Sources
The cash flow statement, dividends per share and diluted share count in each 10-K's XBRL; Part II Item 2 of each 10-Q for monthly buybacks; offering prospectuses (S-3, 424B) for new shares; Form D data sets for private raises.
Also
CEO pay: what the CEO was paid over the same years.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CGON/export.csv") into a cell.